Reviewing Aspire Biopharma (ASBP) and Its Rivals

Aspire Biopharma (NASDAQ:ASBP – Get Free Report) is one of 148 publicly-traded companies in the “Automobile Components” industry, but how does it contrast to its competitors? We will compare Aspire Biopharma to similar businesses based on the strength of its analyst recommendations, institutional ownership, earnings, profitability, valuation, risk and dividends.

Valuation & Earnings

This table compares Aspire Biopharma and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aspire Biopharma $10,000.00 -$24.48 million -0.12
Aspire Biopharma Competitors $6.51 billion $73.97 million 3.28

Aspire Biopharma’s competitors have higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Automobile Components” companies are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by company insiders. Comparatively, 19.6% of shares of all “Automobile Components” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aspire Biopharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aspire Biopharma -11,362.21% N/A -177.59%
Aspire Biopharma Competitors -40.97% -0.26% -1.95%

Volatility and Risk

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Aspire Biopharma’s competitors have a beta of 3.88, suggesting that their average share price is 288% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aspire Biopharma and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspire Biopharma 1 0 0 0 1.00
Aspire Biopharma Competitors 1094 4512 6146 203 2.46

As a group, “Automobile Components” companies have a potential upside of 64.71%. Given Aspire Biopharma’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Aspire Biopharma has less favorable growth aspects than its competitors.

Summary

Aspire Biopharma competitors beat Aspire Biopharma on 12 of the 13 factors compared.

About Aspire Biopharma

(Get Free Report)

Aspire Biopharma is a biopharmaceutical company developing drug products that use sublingual delivery, in which a medicine is placed under the tongue for absorption. Its platform is intended to create rapidly absorbed formulations of existing drugs. The company has highlighted sublingual formulations based on aspirin and caffeine among its product candidates. These are under development; Aspire’s focus is on developing potential therapies rather than marketing an established portfolio of approved products.

Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.